Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia

被引：0
|
作者：
Kim Dalziel
Ali Round
Ruth Garside
Ken Stein
机构：
[1] Peninsula Medical School,Peninsula Technology Assessment Group
[2] Universities of Exeter and Plymouth,Peninsula Technology Assessment Group (PenTAG), Peninsula Medical School
来源：
PharmacoEconomics | 2005年 / 23卷
关键词：
Imatinib; Bone Marrow Transplantation; Chronic Myeloid Leukaemia; Blast Crisis; Cytogenetic Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To evaluate the cost utility of imatinib compared with interferon (IFN)-α or hydroxycarbamide (hydroxyurea) for first-line treatment of chronic myeloid leukaemia.
引用
收藏
页码：515 / 526
页数：11
相关论文
共 50 条
  • [1] First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter
    Belohlavkova, Petra
    Steinerova, Katerina
    Karas, Michal
    Skoumalova, Iva
    Rohon, Peter
    Indrak, Karel
    Voglova, Jaroslava
    Vrbacky, Filip
    Cmunt, Eduard
    Necasova, Tereza
    Kristkova, Zlatuse
    Trneny, Marek
    Zak, Pavel
    Papajik, Tomas
    Faber, Edgar
    LEUKEMIA RESEARCH, 2019, 81 : 67 - 74
  • [2] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
  • [3] Updated estimates of survival and cost effectiveness for imatinib versus interferon-α plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia
    Reed S.D.
    Anstrom K.J.
    Li Y.
    Schulman K.A.
    PharmacoEconomics, 2008, 26 (5) : 435 - 446
  • [4] Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis
    Sheng, Guangying
    Chen, Suning
    Dong, Chaohui
    Zhang, Ri
    Miao, Miao
    Wu, Depei
    Tan, Seng Chuen
    Liu, Chao
    Xiong, Tengbin
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (04) : 371 - 381
  • [5] Ponatinib in chronic myeloid leukaemia: ready for first-line?
    Breccia, Massimo
    Alimena, Giuliana
    LANCET HAEMATOLOGY, 2015, 2 (09): : E352 - E353
  • [6] Introduction of Imatinib as First-line Therapy for Chronic Myeloid Leukemia in Cuba
    Pavon, Valia
    Gomez, Rafael
    Jaime, Juan C.
    Hernandez, Porfirio
    Arencibia, Alberto
    Espinosa-Martinez, Edgardo
    Avila, Onel M.
    Hernandez, Carlos
    Gonzalez, Alejandro
    Carnot, Jose
    Espinosa-Estrada, Edgardo
    Lam, Rosa M.
    Amor, Ana M.
    Lavauth, Kalia
    Hernandez, Annia
    MEDICC REVIEW, 2011, 13 (01) : 36 - 41
  • [7] Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors
    Angstreich, GR
    Matsui, W
    Huff, CA
    Vala, MS
    Barber, J
    Hawkins, AL
    Griffin, CA
    Smith, GBD
    Jones, RJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 130 (03) : 373 - 381
  • [8] First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate
    Eskazan, Ahmet Emre
    Ayer, Mesut
    Kantarcioglu, Bulent
    Arica, Deniz
    Demirel, Naciye
    Aydin, Demet
    Yalniz, Fevzi Firat
    Elverdi, Tugrul
    Salihoglu, Ayse
    Ar, Muhlis Cem
    Aydin, Seniz Ongoren
    Baslar, Zafer
    Aydin, Yildiz
    Tuzuner, Nukhet
    Ozbek, Ugur
    Soysal, Teoman
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (01) : 139 - 141
  • [9] Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses
    Pavey, T.
    Hoyle, M.
    Ciani, O.
    Crathorne, L.
    Jones-Hughes, T.
    Cooper, C.
    Osipenko, L.
    Venkatachalam, M.
    Rudin, C.
    Ukoumunne, O.
    Garside, R.
    Anderson, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (42) : 1 - +
  • [10] Second-Generation Tyrosine Kinase Inhibitors in First-Line Treatment of Chronic Myeloid Leukaemia (CML)
    Elisabetta Abruzzese
    Massimo Breccia
    Roberto Latagliata
    BioDrugs, 2014, 28 : 17 - 26
12345